{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 81 of 169', 'The biomarker results from the small panel will be presented in the CTR, whereas results', 'from the large panel (assessed at selected trial sites) will be presented in a separate report.', '10.5.2.2 Small biomarker panel (all subjects)', 'All subjects will have blood samples taken for analysis of a small panel of biomarkers. The', 'biomarkers to be analysed include, but are not limited to, the following: periostin, DPP4,', 'CCL17 (also known as thymus and activation regulated chemokine [TARC]), IL-13, IL-17,', 'IL-22, and beta-defensin 4A (DEFB4A). These samples will be taken according to the SoP', '(Section 4). LEO may only analyse samples from a subset of subjects.', '10.5.2.3 Large biomarker panel (selected trial sites)', 'At selected trial sites, subjects will be asked to participate in additional biomarker testing.', 'Participation in this component of the trial which also includes skin microbiome', 'characterisation and skin biopsies requires that the subject provides additional informed', 'consent.', 'Subjects consenting to additional biomarker testing will have an extra blood sample taken to', 'measure additional serum biomarkers. These samples will be taken according to the SoP', '(Section 4). To allow unbiased biomarker discovery, a large panel of biomarkers will be', 'assessed.', '10.5.3 Skin biopsies (selected trial sites)', 'At selected trial sites, subjects will be asked to participate in an exploratory component', 'involving skin biopsies. Participation in this component of the trial which also includes skin', 'microbiome characterisation and additional serum biomarker testing requires that the subject', 'provides additional informed consent.', 'Two 3 mm skin biopsies (1 for histology, 1 for gene expression analysis) must be taken from', 'lesional skin at the time-points specified in the SoP (Section 4). At baseline, 2 skin biopsies', 'will also be taken from non-lesional skin at an anatomically similar site (i.e., a total of', '4 biopsies at baseline). The lesional skin biopsies must be taken from the same lesion used for', 'microbiome characterisation (Section 10.5.1.3). The body location of each site will be', 'documented in the eCRF (upper limb, lower limb, trunk).', 'A check of skin biopsy wound healing including removal of suture, if applicable, will be', 'performed at the next trial visit (i.e., at Weeks 2, 6, and 18).', 'Collection, handling and shipment instructions for skin biopsy samples are provided in a', 'separate laboratory manual.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 82 of 169', 'The biopsies will be analysed for expression of markers of inflammation and skin barrier', 'integrity by histology/immunohistochemistry and gene expression analysis.', 'The biomarkers to be analysed include, but are not limited to, the following:', 'Histology/immunohistochemistry/in-situ hybridisation', 'T cells (e.g., CD3+ and CD8+), dendritic cells (e.g., CD11c+, FccR1),', 'monocytes/macrophages (e.g., CD68), epidermal markers (e.g., epidermal', 'thickness, keratin type I cytoskeletal 16, proliferation marker protein Ki-67,', 'protein S100-A, filaggrin, loricrin).', 'Gene expression analysis', 'Global gene expression analysis by RNA sequencing.', 'Quantitative real-time polymerase chain reaction (qPCR) analysis of the', 'following genes: IL-1B, IFNG, IL-13, IL-31, CCL17 (TARC), CCL26, C-X-C', 'motif chemokine ligand 10 (CXCL10), IL-12/IL-23p19, IL-17A, CCL20,', 'IL-19, IL-20, IL-22, S100A9, S100A12.', 'Rationale for selection of biomarkers in biopsies', 'The biomarkers to be analysed in the biopsies have been selected to assess the effect of IL-13', 'inhibition on cell types and cytokines that play a key role in AD skin. Effective treatments of', 'AD are known to reduce the number of inflammatory cells in lesional skin as well as to', 'modulate epidermal markers towards a non-diseased phenotype (25). A quantitative real-time', 'polymerase chain reaction analysis of markers of specific subsets of T cells (e.g., Th1, Th2,', 'Th17, and Th22) will allow analysis of the mechanism of action of tralokinumab in diseased', 'AD skin.', 'Overall, the results from the analyses of biopsy material will be included in the CTR, except', 'the global gene expression analysis which will be presented in a separate report.', '10.5.4 Storage of biological samples', 'Samples collected as part of the exploratory component (microbiome characterisation,', 'biomarkers, and skin biopsies) will be retained for as long as the quality of the material', 'permits evaluation but for no longer than 12 months after completion of the CTR unless', 'specific additional consent has been obtained that allows storage for future research (see', 'below).', 'Biobank', 'This protocol includes the collection and analysis of different biological samples. If consent is', 'given by the subject, LEO will store samples collected as part of the exploratory component', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}